On the other hand, our analysis allowed us to detect significant molecular changes in patients otherwise labeled as TN – one with TP53 p.Arg248Leu – a widely described, pathogenic hotspot gain of function mutation– and RUNX1 p.Arg423Gly variant - undescribed previously, here associated with apparent features of MPN (11). This evidence concerns the gene RUNX1 and myeloproliferative neoplasm.